Pines Wealth Management
VRTX icon

Pines Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Pines Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$209K Sell
400
-8
-2% -$4.1K 0.06% 219
2026
Q2 		$203K Buy
+408
New +$181K 0.06% 217
2025
Q2 		– Sell
-435
Closed -$205K – 235
2025
Q1 		$205K Buy
+435
New +$203K 0.1% 193

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Pines Wealth Management's VRTX Position: Q3 2026 in Review

Pines Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2% in Q3 2026, selling an estimated $4.1K and leaving 400 shares worth $209K. The position accounts for 0.06% of the portfolio, ranked #219.

Pines Wealth Management first reported a position in VRTX in Q1 2025 and has held it in 3 quarters since. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Pines Wealth Management held 400 shares of Vertex Pharmaceuticals worth $209K as of Q3 2026.
  • Pines Wealth Management sold 8 Vertex Pharmaceuticals shares in Q3 2026, an estimated $4.1K.
  • Vertex Pharmaceuticals made up 0.06% of Pines Wealth Management's portfolio in Q3 2026, its #219 holding.
  • Pines Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Pines Wealth Management's 13F filing for Q3 2026, filed 21 Oct 2026.